SMSPHARMA
SMS Pharmaceuticals Limited (SMSPHARMA) Stock Analysis
SMS Pharmaceuticals Limited manufactures APIs and formulations across therapeutic areas including anti-infectives and CNS. It supplies domestic and export markets with manufacturing plants in Andhra Pradesh. The company operates in bulk drugs and finished dosage forms. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - General
₹410.10
+2.76% 1W | +62.30% 52W
Market Cap
3.8k CR
P/E Ratio
37
52W High
₹482
52W Low
₹242.2
Div. Yield
0.09%
Beta
0.3
50 DMA
₹381.6
200 DMA
₹370.2
Profit Margin
11.4%
Inst. Own.
2.9%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 | 210 | 238 | 207 |
| Expenses | 109 | 139 | 132 | 212 | 131 | 165 | 140 | 207 | 157 | 194 | 167 | 198 | 166 |
| Operating Profit | 26 | 28 | 29 | 34 | 34 | 31 | 33 | 41 | 39 | 48 | 44 | 40 | 41 |
| OPM % | 19% | 17% | 18% | 14% | 20% | 16% | 19% | 16% | 20% | 20% | 21% | 17% | 20% |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 2 |
| Interest | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 | 6 | 5 | 6 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 | 34 | 31 | 27 | 27 |
| Tax % | 31% | 21% | 26% | 26% | 25% | 29% | 24% | 30% | 23% | 26% | 26% | 23% | 26% |
| Net Profit | 9 | 12 | 11 | 17 | 16 | 14 | 18 | 20 | 20 | 25 | 23 | 33 | 21 |
| EPS in Rs | 1.10 | 1.38 | 1.36 | 2.04 | 1.95 | 1.66 | 2.15 | 2.29 | 2.31 | 2.70 | 2.51 | 3.49 | 2.23 |
| Metric | Mar 2007 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 193 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 887 | 898 |
| Expenses | 145 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 593 | 644 | 716 | 725 |
| Operating Profit | 47 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 139 | 171 | 173 |
| OPM % | 25% | 15% | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 16% | 18% | 19% | 19% |
| Other Income | 5 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 8 | 9 |
| Interest | 8 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 | 19 | 23 | 23 |
| Depreciation | 5 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 | 34 | 40 | 40 |
| Profit before tax | 40 | 56 | 42 | 60 | 62 | 51 | 91 | 68 | 5 | 66 | 92 | 117 | 119 |
| Tax % | 36% | 26% | 14% | 33% | 34% | 36% | 33% | 1% | 28% | 26% | 27% | 25% | |
| Net Profit | 25 | 41 | 28 | 32 | 40 | 32 | 63 | 62 | -7 | 50 | 69 | 102 | 102 |
| EPS in Rs | 2.55 | 4.83 | 3.36 | 3.75 | 4.73 | 3.73 | 7.38 | 7.35 | -0.83 | 5.88 | 7.80 | 10.89 | 10.93 |
| Dividend Payout % | 8% | 4% | 6% | 7% | 5% | 7% | 4% | 4% | -36% | 7% | 5% | 4% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 19.0% | 10.0% | 4.0% |
| Profit CAGR | 155.0% | 10.0% | 10.0% |
Shareholding Pattern
Promoters66.27%
FIIs0.03%
DIIs3.03%
Public30.68%
Promoters68.07%
FIIs0.28%
DIIs2.88%
Public28.77%
Promoters68.07%
FIIs0.04%
DIIs3.21%
Public28.69%
Promoters68.07%
FIIs0.31%
DIIs3.02%
Public28.60%
Promoters68.07%
FIIs0.65%
DIIs2.83%
Public28.45%
Promoters64.29%
FIIs0.59%
Public35.12%
Promoters64.67%
FIIs0.17%
DIIs1.98%
Public33.18%
Promoters66.27%
FIIs0.08%
DIIs2.43%
Public31.23%
Promoters68.07%
FIIs0.31%
DIIs3.02%
Public28.60%
Promoters68.07%
FIIs0.65%
DIIs2.83%
Public28.45%
SMSPHARMA
Holdings Analysis
Key strengths & risk signals
77
Overall
61
Fundamental
94
Technical
Risks (1)
NEGLIGIBLE DIVIDEND! 0.09% yield - little to no income.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (381.6) is above 200-day average (370.2) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
EXCELLENT YEAR! Stock gained 62.3% in the last year.
Fundamental & Technical Analysis
77Overall
61Fundamental
94Technical
Fundamental Breakdown
Growth Quality
15/30
Revenue CAGR: 19.3% (VERY GOOD, 13/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.4% profit margin - acceptable profitability.
PEG Valuation
8/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.09% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 35.01% public ownership - moderate retail influence.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (381.6) is above 200-day average (370.2) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (410.1) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 62.3% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 1,234,302 vs down days: 455,463. Ratio: 2.71x
RSI
3/5
NEUTRAL! RSI at 56.4 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 70.0% of 52W range - positive territory.
Momentum
4/5
GOOD MOMENTUM! Price has grown across all timeframes - up 2.8% (1 week), 13.5% (1 month), 9.1% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
SMSPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-30 | Concall PDF | |
| Q2FY262025-11-13 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - General · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMSPHARMA | ₹410.10 | 37 | 11.4% | 19.3% | – | +62.3% | 77 | BREAKOUT | +2.0% | -36.1% | +5.6% | -13.0% |
| SAIPARENT | ₹506.40 | 113.8 | 3.9% | 126.1% | 111.8% | +29.0% | 69 | APPROACHING RESISTANCE | +464.3% | -1,416.7% | +435.0% | -33.6% |
| NGLFINE | ₹2,581.80 | 27.8 | 10.7% | 21.8% | 32.9% | +86.7% | 76 | APPROACHING SUPPORT | +100.0% | +36.3% | +33.6% | -6.7% |
| TTKHLTCARE | ₹1,074.60 | 20.5 | 8.3% | 5.9% | -53.2% | -5.4% | 65 | BREAKDOWN | +63.8% | -2.3% | +13.8% | +18.2% |
| KOPRAN | ₹249.90 | 48.2 | 3.6% | 7.2% | -1.9% | +34.7% | 69 | BREAKOUT | -9.5% | -64.6% | +13.9% | -34.2% |
| SENORES | ₹1,416.10 | 50 | 18.7% | 159.1% | 139.2% | +113.7% | 73 | BREAKDOWN | +55.8% | -2.8% | +35.9% | +2.9% |
| SANOFI | ₹3,131.00 | 22.2 | 17.9% | -12.6% | -19.3% | -38.7% | 58 | BREAKDOWN | +20.1% | -18.6% | +7.7% | -7.3% |
| CORONA | ₹2,217.90 | 67.9 | 13.5% | 16.6% | 29.7% | +55.5% | 86 | BREAKOUT | +29.9% | +32.5% | +21.9% | +19.5% |
Data from TradeAlone · Updated daily
